Market Growth and Key Players
Top-selling therapies in 2023 included Yescarta with $1.8 billion in sales, Kymriah with $1.2 billion, and Carvykti with $0.9 billion. The dominant companies in the space are Novartis, Gilead, Bristol-Myers Squibb, and Johnson & Johnson. The United States accounts for 65 percent of global CAR-T therapy revenue, reflecting both the scale of the U.S. health care system and the early adoption of the technology.
A single CAR-T therapy infusion in the United States ranges from $373,000 to $475,000. That figure does not include hospitalization and ancillary costs. Medicare covers CAR-T therapy under the Inpatient Prospective Payment System, and as of 2024, 42 states offer Medicaid coverage for the treatment. The expansion of public insurance has helped broaden access, though the high cost of each infusion remains a barrier for many patients.
Manufacturing Constraints and Innovations
Manufacturing remains a critical bottleneck for CAR-T therapy. For autologous products, which are custom-made from each patient’s own cells, the vein-to-vein time averages three to four weeks. This delay can be difficult for patients with aggressive cancers. To address this, developers are working on allogeneic, off-the-shelf products derived from donor cells that could be manufactured in advance and made available more quickly. The Grand View Research report identifies the development of such products as one of the key drivers of the projected market growth, alongside expanding manufacturing capacity.
The field has its roots in earlier work with tumor-infiltrating lymphocytes, or TILs. In the late 1980s, researchers at the National Institutes of Health showed that TILs grown from mouse tumors could shrink tumors when transferred back into the animals. That line of research led to treatments for metastatic melanoma. Scientists then began engineering T cells directly rather than relying on naturally occurring ones, and CAR-T therapy developed from that effort. The first CAR-T treatment received U.S. approval in 2017. Since then, the approach has offered a new option for certain blood cancers that had stopped responding to standard treatments.
Balancing Promise with Caution
The numbers are impressive, but the field carries serious risks. CAR-T therapy is not a cure for every patient, and it can cause cytokine release syndrome and neurological side effects. Although other immunotherapies such as checkpoint inhibitors have helped many patients, a large share of patients still saw their cancers progress. CAR-T therapy emerged as a treatment for those cases, particularly in blood cancers that had failed other therapies.
For readers, the significance is twofold. More approved uses mean more patients may become eligible, but access still depends on insurance coverage and manufacturing capacity. The expansion of Medicare and Medicaid coverage in recent years has helped, but patients should still talk to their doctor about whether CAR-T therapy is an appropriate option for their specific diagnosis and what the financial implications might be. The field is moving quickly. With a projected market of $18.2 billion by 2030, and with manufacturing innovations and new approvals on the horizon, CAR-T therapy is likely to become an increasingly important tool in the fight against cancer. As always, patients should consult their doctor to understand the latest developments and what they might mean for their individual treatment plan.
{“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “CAR-T Therapy Market Soars with $3.9B in Sales, U.S. Leads Growth”, “description”: “Market Growth and Key Players Top-selling therapies in 2023 included Yescarta with $1.8 billion in sales, Kymriah with $1.2 billion, and Carvykti with $0.9 billion….”, “datePublished”: “2026-07-07T09:30:00+00:00”, “author”: {“@type”: “Person”, “name”: “Reza Karimi”}, “publisher”: {“@type”: “Organization”, “name”: “InfoPulse Today”, “url”: “https://newsfeed.infopulsetoday.com/”}}
